Tofacitinib has been FDA-approved for psoriatic arthritis (PsA), whereas baricitinib (31) (the JAK1 and JAK2 inhibitor) and upadacitinib (32) (the selective JAK1 inhibitor) have been FDA-approved for RA (Table 1). This evidence concerns the gene JAK2 and rheumatoid arthritis.